{"nctId":"NCT04672252","briefTitle":"The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy","startDateStruct":{"date":"2020-12-01","type":"ACTUAL"},"conditions":["Pain, Postoperative"],"count":100,"armGroups":[{"label":"Cohort 1 - CBD","type":"EXPERIMENTAL","interventionNames":["Drug: CBD Oral Disintegrating Tablet (ODT)"]},{"label":"Cohort 2 - Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo ODT"]}],"interventions":[{"name":"CBD Oral Disintegrating Tablet (ODT)","otherNames":[]},{"name":"Placebo ODT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Patients undergoing an arthroscopic shoulder procedure (rotator cuff repair, decompression, labrum repair)\n* Patients ages 18-75, inclusive\n* Female patients must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly\n* Male patients must be using an effective form of contraception\n\nExclusion Criteria\n\n* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)\n* Younger than 18 years of age\n* Older than 75 years of age\n* Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners\n* History of cannabis abuse or dependence\n* History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values\n* History of stroke or acute coronary syndromes within 3 months before surgery\n* Abnormal coagulation profile\n* Renal failure (serum creatinine \\> 250 Î¼mol/L \\[2.83 mg/dL\\]) or liver cirrhosis\n* Patients with a history of hypersensitivity to Percocet\n* Patients that have been on pre-operative opioid management for any reason\n* Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder\n* Patients diagnosed with major depression, psychosis, or substance abuse disorder\n* Patients with current or a history of suicidal ideation\n* Breastfeeding females\n* Patients with clinically significant illness, including cardiovascular disorders\n* Clinically significant lab abnormalities\n* Abnormal LFTs\n* Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures\n* Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).\n* Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly\n* Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly\n* Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Visual Analog Scale (VAS) Score","description":"Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"3.1"},{"groupId":"OG001","value":"5.7","spread":"3.2"}]}]}]},{"type":"PRIMARY","title":"Pain Visual Analog Scale (VAS) Score","description":"Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.8"},{"groupId":"OG001","value":"5.3","spread":"2.6"}]}]}]},{"type":"PRIMARY","title":"Pain Visual Analog Scale (VAS) Score","description":"Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.9"},{"groupId":"OG001","value":"3.2","spread":"2.7"}]}]}]},{"type":"PRIMARY","title":"Pain Visual Analog Scale (VAS) Score","description":"Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.4"},{"groupId":"OG001","value":"2.3","spread":"2.4"}]}]}]},{"type":"PRIMARY","title":"Nausea Score on VAS Scale","description":"Any nausea experienced by the patients will be recorded by use of a VAS (0 = no nausea, 10 = worst nausea imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.6"},{"groupId":"OG001","value":"2.5","spread":"3.1"}]}]}]},{"type":"PRIMARY","title":"Nausea Score on VAS Scale","description":"Any nausea experienced by the patients will be recorded by use of a VAS (0 = no nausea, 10 = worst nausea imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.1"},{"groupId":"OG001","value":"0.6","spread":"2.1"}]}]}]},{"type":"PRIMARY","title":"Nausea Score on VAS Scale","description":"Any nausea experienced by the patients will be recorded by use of a VAS (0 = no nausea, 10 = worst nausea imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.4"},{"groupId":"OG001","value":"0.5","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Total Opioid Consumption","description":"Consumption based on patient-self-report","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"12"},{"groupId":"OG001","value":"19.7","spread":"13.6"}]}]}]},{"type":"SECONDARY","title":"Total Opioid Consumption","description":"Consumption based on patient-self-report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"18.7"},{"groupId":"OG001","value":"16.7","spread":"36.6"}]}]}]},{"type":"SECONDARY","title":"Total Opioid Consumption","description":"Consumption based on patient-self-report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":"53.2"},{"groupId":"OG001","value":"67.3","spread":"55.2"}]}]}]},{"type":"SECONDARY","title":"Total Opioid Consumption","description":"Consumption based on patient-self-report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":"19.3"},{"groupId":"OG001","value":"10.3","spread":"22.7"}]}]}]},{"type":"SECONDARY","title":"Number of Completed Doses Out of 3 Maximum Doses/Day","description":"Based on patient-self-report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.27"},{"groupId":"OG001","value":"3","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Completed Doses Out of 3 Maximum Doses/Day","description":"Based on patient-self-report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"0"},{"groupId":"OG001","value":"2.7","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Number of Completed Doses Out of 3 Maximum Doses/Day","description":"Based on patient-self-report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.4"},{"groupId":"OG001","value":"2.7","spread":"1"}]}]}]},{"type":"SECONDARY","title":"Patient Satisfaction Score","description":"Patients will record their satisfaction with their management, on a 0-10 scale (where 0= not at all satisfied; and 10 = completely satisfied).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"3"},{"groupId":"OG001","value":"5.6","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Patient Satisfaction Score","description":"Patients will record their satisfaction with their management, on a 0-10 scale (where 0= not at all satisfied; and 10 = completely satisfied).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"2.5"},{"groupId":"OG001","value":"6","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Patient Satisfaction Score","description":"Patients will record their satisfaction with their management, on a 0-10 scale (where 0= not at all satisfied; and 10 = completely satisfied).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":"2.6"},{"groupId":"OG001","value":"7.9","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Patient Satisfaction Score","description":"Patients will record their satisfaction with their management, on a 0-10 scale (where 0= not at all satisfied; and 10 = completely satisfied).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"2.3"},{"groupId":"OG001","value":"8.5","spread":"2.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Elevated alanine transaminase"]}}}